Literature DB >> 26001699

The vascular phenotype of children with systemic lupus erythematosus.

Catherine Quinlan1, Jameela Kari, Clarissa Pilkington, John Deanfield, Rukshana Shroff, Stephen D Marks, Kjell Tullus.   

Abstract

BACKGROUND: The increased risk of cardiovascular disease (CVD) in adults with systemic lupus erythematosus (SLE) has been known since the 1970s, but studies in juvenile-onset SLE (JSLE) have reported conflicting results and more data are needed. The aim of this cross-sectional study was to establish the baseline risk of CVD in a cohort of UK patients with JSLE.
METHODS: Data were collected to establish disease duration, disease activity, medication use and activity levels, as well as demographic data, including family history of CVD. Vascular phenotype was established using well-validated measures of carotid intima media thickness (cIMT) and pulse wave velocity (PWV).
RESULTS: In total, 45 children (39 female; mean age 13.5 ± 2.9 years) with JSLE were recruited to the study. Of these, 24 had a history of biopsy-proven lupus nephritis and five had an estimated glomerular filtration rate of <90 ml/min/1.73 m(2). Comparison of these JSLE patients with healthy controls previously scanned at our hospital revealed that the cIMT value was significantly higher in the former (0.45 vs. 0.37 mm, respectively; p < 0.0001). This difference was associated with the use of antihypertensives (p = 0.04) and higher or lower doses of prednisolone (p < 0.0001). PWV was not significantly different in the patient and control group (5.27 vs. 5.34 m/s, respectively; p = 0.77). In the patient group, the mean body mass index percentile was 65.63 ± 28.8, and the median physical activity score was 1,773 (676-2,854) metabolic equivalents of task (METs). None of the patients admitted to cigarette smoking, and ten had a positive family history of cardiovascular disease (CVD).
CONCLUSION: This study shows that our patients with JSLE had increased cIMT without an increase in PWV, suggesting possible early adaptive changes in JSLE. Follow-up data are needed to determine whether these changes result in clinically significant CVD.

Entities:  

Mesh:

Year:  2015        PMID: 26001699     DOI: 10.1007/s00467-015-3059-9

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  48 in total

1.  BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus.

Authors:  D A Isenberg; A Rahman; E Allen; V Farewell; M Akil; I N Bruce; D D'Cruz; B Griffiths; M Khamashta; P Maddison; N McHugh; M Snaith; L S Teh; C S Yee; A Zoma; C Gordon
Journal:  Rheumatology (Oxford)       Date:  2005-04-06       Impact factor: 7.580

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.

Authors:  Stacy P Ardoin; Laura Eve Schanberg; Christy I Sandborg; Huiman X Barnhart; Greg W Evans; Eric Yow; Kelly L Mieszkalski; Norman T Ilowite; Anne Eberhard; Lisa F Imundo; Yuki Kimura; Deborah Levy; Emily von Scheven; Earl Silverman; Suzanne L Bowyer; L Punaro; Nora G Singer; David D Sherry; Deborah K McCurdy; Marissa Klein-Gitelman; Carol Wallace; Richard M Silver; Linda Wagner-Weiner; Gloria C Higgins; Hermine I Brunner; Lawrence Jung; Jennifer B Soep; Ann M Reed; Susan D Thompson
Journal:  Ann Rheum Dis       Date:  2013-02-22       Impact factor: 19.103

4.  Premature cardiovascular disease in patients with systemic lupus erythematosus influences survival after renal transplantation.

Authors:  Gudrun E Norby; Torbjørn Leivestad; Geir Mjøen; Anders Hartmann; Karsten Midtvedt; Jan T Gran; Hallvard Holdaas
Journal:  Arthritis Rheum       Date:  2011-03

5.  Three decades of progress in treating childhood-onset lupus nephritis.

Authors:  Tanya Pereira; Carolyn L Abitbol; Wacharee Seeherunvong; Chryso Katsoufis; Jayanthi Chandar; Michael Freundlich; Gastón Zilleruelo
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-28       Impact factor: 8.237

6.  Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients.

Authors:  S Sazliyana; M S Mohd Shahrir; C T Norella Kong; H J Tan; B B Hamidon; M T Azmi
Journal:  Lupus       Date:  2011-08-15       Impact factor: 2.911

7.  Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus.

Authors:  Patricia Katz; Steven Gregorich; Jinoos Yazdany; Laura Trupin; Laura Julian; Edward Yelin; Lindsey A Criswell
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-02       Impact factor: 4.794

Review 8.  Cardiovascular risk assessment in children with chronic kidney disease.

Authors:  Rukshana Shroff; Arianna Dégi; Andrea Kerti; Eva Kis; Orsolya Cseprekál; Kálmán Tory; Attila J Szabó; George S Reusz
Journal:  Pediatr Nephrol       Date:  2012-10-16       Impact factor: 3.714

9.  The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus.

Authors:  S D Marks; C Pilkington; P Woo; M J Dillon
Journal:  Rheumatology (Oxford)       Date:  2004-06-29       Impact factor: 7.580

10.  Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study.

Authors:  Johanna Gustafsson; Iva Gunnarsson; Ola Börjesson; Susanne Pettersson; Sonia Möller; Guo-Zhong Fei; Kerstin Elvin; Julia F Simard; Lars-Olof Hansson; Ingrid E Lundberg; Anders Larsson; Elisabet Svenungsson
Journal:  Arthritis Res Ther       Date:  2009-12-10       Impact factor: 5.156

View more
  3 in total

Review 1.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

2.  Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.

Authors:  Julien Hogan; Astrid Godron; Véronique Baudouin; Theresa Kwon; Jérôme Harambat; Georges Deschênes; Olivier Niel
Journal:  Pediatr Nephrol       Date:  2017-08-05       Impact factor: 3.714

3.  Metabolomics Defines Complex Patterns of Dyslipidaemia in Juvenile-SLE Patients Associated with Inflammation and Potential Cardiovascular Disease Risk.

Authors:  George A Robinson; Junjie Peng; Ines Pineda-Torra; Coziana Ciurtin; Elizabeth C Jury
Journal:  Metabolites       Date:  2021-12-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.